On June 6, 2017 NantKwest and Nantworks reported at the 2017 Annual American Society for Clinical Oncology meeting (ASCO) (Free ASCO Whitepaper) in Chicago, IL the expansion of the company’s existing NANT Cancer Vaccine program in pancreatic cancer (ClinicalTrials.gov NCT03136406) to target a number of additional tumor types (Press release, NantKwest, JUN 6, 2017, http://ir.nantkwest.com/phoenix.zhtml?c=254059&p=RssLanding&cat=news&id=2279115 [SID1234519440]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The NANT Cancer Vaccine program is a personalized, molecularly-informed therapy guided by NantHealth’s GPS Cancer test that includes the simultaneous combination of off the shelf natural killer cells (NK) with the endogenous activation of dendritic, T cell and NK cells to more fully enhance the innate and adaptive immune system of cancer patients.

The NANT Cancer Vaccine is the first combination immunotherapy protocol formulated to include the novel delivery of metronomic, low-dose chemotherapy and radiation with molecularly-informed, tumor-associated antigen vaccines, together with NantKwest’s NK cell therapy, to induce immunogenic cell death while avoiding the ravages of toxic high dose chemotherapy.

By inducing immunogenic cell death and enhancing a patient’s innate and adaptive immune system, the NANT Cancer Vaccine is designed to attain a long-term, durable response in multiple cancer types with lower toxicity and higher efficacy in comparison with current standards of care.

"Current therapeutic approaches to the treatment of cancer are often inadequate to fully activate a patient’s immune response. Through the NANT Cancer Vaccine program, we believe we can help facilitate a paradigm shift in cancer care with the first clinical program formulated to incorporate low dose, metronomic chemotherapy and radiation, combined with molecularly-informed tumor associated antigens that are designed to activate dendritic and T cells by adenoviral and yeast vaccine vectors, together with both endogenous (IL-15) and exogenous (off the shelf) activation of NantKwest’s NK cell therapy," said Patrick Soon-Shiong, Chairman and CEO of NantKwest.

Dr. Soon-Shiong continued, "In addition to the previously announced Pancreatic Cancer Vaccine, we are now actively working to initiate multiple clinical trials across a wide range of cancer types which include: Lung, breast, head and neck cancer, colon, melanoma, ovarian, urothelial, Hodgkins and non-Hodgkins lymphoma, sarcoma, and Merkel cell carcinoma, all based on a similar treatment protocol and designed to more fully harness the power of the immune system and improve cancer patient outcomes."